Comparative Study of Two Tenecteplase Therapeutic Protein Purification Methods

Document Type : Research(Original) Article


Iranian Academic Center for Education, Culture & Research (ACECR)‐Fars Branch Department of Human Genetics Research, Shiraz, Iran


Therapeutic Tenecteplase (TNKase) is a recombinant and site directed mutant version of human tissue plasminogen activator (TPA) with clinical advantages over TPA. Due to specific glycosylation, TNKase is preferred to over-express in mammalian cell lines such as Chinese Hamster Ovarian (CHO) Cells. The production and purification of this protein need huge efforts and costs, which directly increase the end product price and limits its medical applications in developing countries despite its benefits. In the current study, we compared two purification methods in order to minimize purification steps as well as purification costs. In the first method, DMEM medium containing CHO-C111 cells expressed recombinant TNKase was purified by a three columns protocol including Sephadex® G-10, HiPrepTM CM FF and L-lysine HyperD®. In the second method, because of its properties, only L-lysine HyperD® column was applied for purification of protein molecules with the lysine binding site, including TNKase. Our results showed that in the second method, higher purification fold and purification yield (1.14 and 1.25 times, respectively) have achieved compared to the first method. This finding in addition to reduction in purification steps, purification cost and time, make it possible to use this method for purification of TNKase. In addition, we suggest overexpressing this protein in serum-free cell lines such as CHO-DG44 in order to minimize impurities and make purification procedure easier.


1. Davydov L, Cheng JW. Tenecteplase: a review. Clinical therapeutics. 2001;23(7):982-97. doi: 10.1159/000200455.
2. Dunn CJ, Goa KL. Tenecteplase. American Journal of Cardiovascular Drugs. 2001;1(1):51-66. doi: 10.2165/00129784-200101010-00006.
3. Baird AE, Jackson R, Jin W. Tenecteplase for Acute Ischemic Stroke Treatment. Seminars in Neurology. 2021: 41(1):28-38. doi: 10.1055/s-0040-1722722.
4. Manosroi J, Tayapiwatana C, Götz F, Werner RG, Manosroi A. Secretion of active recombinant human tissue plasminogen activator derivatives in Escherichia coli. Applied and environmental Microbiology. 2001;67(6):2657-64. doi: 10.1128/AEM.67.6.2657-2664.2001.
5. Collen D, Lijnen HR. The tissue-type plasminogen activator story. Arteriosclerosis, thrombosis, and vascular biology. 2009;29(8):1151-5. doi: 10.1161/atvbaha.108.179655.
6. Pohl G, Kaellstroem M, Bergsdorf N, Wallen P, Joernvall H. Tissue plasminogen activator: peptide analyses confirm an indirectly derived amino acid sequence, identify the active site serine residue, establish glycosylation sites, and localize variant differences. Biochemistry. 1984;23(16):3701-7. doi: 10.1021/bi00311a020.
7. Wikström K, Mattsson C, Sterky C, Pohl G. Tissue plasminogen activator mutants lacking the growth factor domain and the first kringle domain: II: Enzymatic properties in plasma and in vivo thrombolytic activity and clearance rates in rabbits. Fibrinolysis. 1991;5(1):31-41. doi: 10.1016/0268-9499(91)90075-F.
8. Dormiani K, Khazaie Y, Forouzanfar M, Ghaedi K, Mofid MR, Karbalaie K, et al. Creation of Tenecteplase-Producing CHO Cell Line Using Site-Specific Integrase from the Phage ϕC31. Yakhteh Medical Journal. 2010;12(2).
9. Zhu Y, Zhang X, Zhu J, Zhao Q, Li Y, Li W, et al. Cytotoxicity of phenol red in toxicity assays for carbon nanoparticles. Int J Mol Sci. 2012;13(10):12336-48. doi: 10.3390/ijms131012336.
10. Chen H, Zhu Z, Yu H, Lu JJ, Liu S. Simple means for fractionating protein based on isoelectric point without ampholyte. Analytical chemistry. 2016;88(18):9293-9. doi: 10.1021/acs.analchem.6b02856.
11. Shaw KL, Grimsley GR, Yakovlev GI, Makarov AA, Pace CN. The effect of net charge on the solubility, activity, and stability of ribonuclease Sa. Protein Sci. 2001;10(6):1206-15. doi: 10.1110/ps.440101.
12. Estcourt LJ, Desborough M, Brunskill SJ, Doree C, Hopewell S, Murphy MF, et al. Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders. Cochrane Database of Systematic Reviews. 2016(3). doi: 10.1002/14651858.CD009733.pub3.
13. Cafiero T, Toledo A. Borrelia burgdorferi surface exposed GroEL is a multifunctional protein. Pathogens. 2021;10(2):226. doi: 10.3390/pathogens10020226.
14. Llinás M. The Kringle of Life. The Protein Journal. 2021:1-3. doi: 10.1007/s10930-021-10009-6.
15. Gupta V, Sengupta M, Prakash J, Tripathy BC. Production of Recombinant Pharmaceutical Proteins. Basic and Applied Aspects of Biotechnology: Springer; 2017. p. 77-101. doi: 10.1007/978-981-10-0875-7_4.
16. Boi C, Castro C, Sarti GC. Plasminogen purification from serum through affinity membranes. Journal of Membrane Science. 2015;475:71-9. doi: 10.1016/j.memsci.2014.10.013.
17. Li P, Gomes PF, Loureiro JM, Rodrigues AE. Proteins separation and purification by expanded bed adsorption and simulated moving bed technology. Continuous processing in pharmaceutical manufacturing. 2014:1-34. doi: 10.1002/9783527673681.ch01.